The Federal Trade Commission sued to block Amgen Inc.’s $27.8 billion deal to buy Horizon Therapeutics Plc, arguing the tie-up would stifle competition for the development of treatments for serious illnesses.
To read the entire story, you must be logged in.
Please log in now or register with us.
